Overview

Study of Aranesp to Treat Anemia in Prostate Cancer Patients.

Status:
Completed
Trial end date:
2005-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if darbepoetin alfa is an effective treatment for anemia in prostate cancer patients and, if so, what dose is most effective. Sometimes prostate cancer patients have low red blood cell counts (low hemoglobin) from various treatments they are receiving, such as chemotherapy. The red blood cells deliver oxygen to the tissue. This then helps give the patient more energy.
Phase:
Phase 2
Details
Lead Sponsor:
University of Washington
Collaborator:
Amgen
Treatments:
Darbepoetin alfa